Evidence review
Do vagus nerve stimulators actually work? What the research says
Modestly, and not for the reason they are usually sold. Meta-analyses find improvements in insomnia and depression scores compared with sham or control, though the reviewers rate the quality of that evidence as low to very low. Meanwhile the single most marketed claim in the category, that these devices raise heart rate variability, is the one that failed: pooling 16 studies in healthy people found strong evidence of no acute effect at all.
This is not medical advice. It is a plain reading of published reviews. Anything about your own health belongs with your clinician.
What the evidence says, outcome by outcome
| Outcome | Finding | Evidence base |
|---|---|---|
| Insomnia and sleep quality | Sleep quality improved, PSQI down 3.60 points and insomnia severity down 5.24 points versus comparison | 6 trials, 336 patients Low to very low (GRADE) |
| Depression | Significant reduction in Hamilton Depression Scale scores, with higher response rates than sham | 12 studies, 838 participants Low to very low |
| Postural tachycardia syndrome | Postural heart rate rise significantly lower than sham after two months | 1 sham controlled RCT, 26 participants Single small trial |
| Heart rate variability, acute, in healthy people | No effect. Strong statistical evidence for the null hypothesis versus sham | 16 single blind studies Strong evidence of no acute effect |
| Safety and tolerability | Well tolerated. Skin irritation where the electrode sits is the most common effect at 18.2 percent | 51 studies, 1,322 people Consistent across reviews |
The HRV claim, which is the one to be careful with
Almost every device in this category is sold on heart rate variability. Higher HRV reads as a calmer, better regulated nervous system, it is easy to measure with a ring or a watch, and it makes a satisfying chart.
In 2021 a group of researchers pooled 16 single blind studies comparing ear stimulation against sham in healthy participants, using a Bayesian approach that can quantify support for the null rather than just failing to find an effect. The result was strong support for the null: acute stimulation did not change vagally mediated HRV compared with sham. Their conclusion was that HRV is not a robust biomarker for acute stimulation.
What that does and does not mean. It was about acute sessions, in healthy people, on one biomarker. It does not test weeks of daily use, it does not cover people with a diagnosed condition, and it does not say the devices do nothing. What it does say is that if you buy one specifically to watch your HRV number rise, the published evidence does not support that expectation.
What does hold up
Sleep. Six trials covering 336 patients with insomnia found meaningful improvement: sleep quality scores down 3.60 points and insomnia severity down 5.24, along with gains in how long people slept and how quickly they fell asleep. The reviewers graded that evidence low and very low respectively.
Mood. Twelve studies covering 838 participants found significant reductions in depression scores and higher response rates than sham. Again graded low to very low.
A specific condition. In postural tachycardia syndrome, a sham controlled randomized trial found the postural heart rate rise significantly lower after two months of daily stimulation. Twenty six people in total.
Notice the pattern. The signal appears in people who have the symptom, not in healthy people optimizing a number. That is the most useful thing on this page for deciding whether to buy one.
How much weight the evidence can carry
Low and very low are not insults, they are technical grades, and they mean roughly this: the studies are small, they run for weeks rather than months, blinding is hard because people can feel the stimulation, and results vary between trials more than you would like.
Low quality evidence of an effect is not the same as evidence of no effect. It means the direction looks favourable and the size is uncertain, and that confident marketing claims are running ahead of what has actually been shown.
The one thing that is well established is safety. Across 51 studies and 1,322 people the most common side effect was skin irritation where the electrode sits, at 18.2 percent, then headache at 3.6 percent, with serious events rare and mostly not attributable to the stimulation.
What this means if you are deciding whether to buy one
Buy for a symptom, not for a metric. If you sleep badly or your stress runs high, the evidence points in a helpful direction. If you feel fine and want a better HRV chart, it does not.
Give it weeks. Every trial that found something ran daily stimulation for one to two months. Three sessions tells you nothing.
Spend accordingly. Since nobody can tell you in advance whether you personally will respond, the size of the bet matters. The devices in this category run from $199 to $900, and only one has published trials naming the hardware itself.
Frequently asked questions
For symptoms, the evidence points modestly yes. Meta-analyses find improvements in insomnia and depression scores versus comparison, though the reviewers themselves rate the quality of that evidence as low to very low. For healthy people trying to raise heart rate variability, a meta-analysis of 16 studies found strong evidence of no acute effect versus sham.
Sources
- Neuromodulation, 2025. Transcutaneous auricular vagus nerve stimulation in insomnia: a systematic review and meta-analysis. 6 trials, 336 patients.
- Journal of Affective Disorders, 2023. Efficacy and safety of transcutaneous auricular vagus nerve stimulation for depression. 12 studies, 838 participants.
- Psychophysiology, 2021. Does taVNS affect vagally mediated heart rate variability? A living Bayesian meta-analysis. 16 studies, strong evidence for the null.
- JACC: Clinical Electrophysiology, 2024. Noninvasive vagus nerve stimulation in postural tachycardia syndrome: a randomized clinical trial. 12 active, 14 sham.
- Brain Stimulation, 2018. Safety and tolerability of transcutaneous vagus nerve stimulation in humans: a systematic review. 51 studies, 1,322 people.